Related Experiment Video
Updated: Apr 12, 2026
07:01
Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
Published on: May 16, 2019
9.7K
Intractable epilepsy and the P-glycoprotein hypothesis.
Guang-Xin Wang1, Da-Wei Wang2, Yong Liu1
1a Medical Institute of Paediatrics , Qilu Children's Hospital of Shandong University , Jinan , P.R. China.
The International Journal of Neuroscience
|May 23, 2015
Summary
Multidrug transporter P-glycoprotein (P-gp) overexpression may cause intractable epilepsy (IE) in patients unresponsive to antiepileptic drugs (AEDs). This review explores evidence linking P-gp to IE across various research areas.
Area of Science:
- Neurology
- Pharmacology
- Genetics
Background:
- Epilepsy affects over 60 million globally.
- Intractable epilepsy (IE) impacts 20-30% of patients resistant to antiepileptic drugs (AEDs).
- Mechanisms of IE are poorly understood, but P-glycoprotein (P-gp) is a potential factor.
Purpose of the Study:
- To review evidence supporting the association between P-gp overexpression and IE.
- To consolidate findings from diverse research fields.
Main Methods:
- Review of animal studies.
- Pharmacological evidence analysis.
- Examination of clinical cases and genetic studies.
Main Results:
- Evidence suggests P-gp overexpression is linked to IE.
- P-gp may mediate drug efflux at the blood-brain barrier.
- This could explain variable patient responses to AEDs.
Conclusions:
- P-gp overexpression is a significant factor in intractable epilepsy.
- Further research into P-gp's role is warranted.
- This understanding may lead to improved IE treatments.
Related Concept Videos
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
1.8K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.8K
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
147
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
147
01:24Epilepsy and Seizures: Overview
1.7K
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.7K
01:20Antiepileptic Drugs: Potassium Channel Activators
1.0K
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
1.0K
01:14Antiepileptic Drugs: Glutamate Antagonists
1.3K
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
1.3K
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
1.2K
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.2K